Shattuck Labs/$STTK
1D1W1MYTD1Y5YMAX
Capital at risk
About Shattuck Labs
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
- Ticker
- $STTK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40
- Headquarters
- Austin, United States
- Website
- www.shattucklabs.com
Shattuck Labs Metrics
BasicAdvanced
$686M
-
-$0.50
1.10
-
Price and volume
Market cap
$686M
Beta
1.1
52-week high
$8.33
52-week low
$1.70
Average daily volume
1.2M
Financial strength
Current ratio
27.587
Quick ratio
26.944
Long term debt to equity
0.009
Total debt to equity
0.013
Profitability
EBITDA (TTM)
-52.14
Gross margin (TTM)
-3,823.90%
Net profit margin (TTM)
-5,256.80%
Operating margin (TTM)
-5,570.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-24.43%
Return on equity (TTM)
-39.21%
Valuation
Price to revenue (TTM)
717.733
Price to book
3.26
Price to tangible book (TTM)
3.26
Price to free cash flow (TTM)
-17.404
Free cash flow yield (TTM)
-5.75%
Free cash flow per share (TTM)
-0.393
Growth
Revenue change (TTM)
-66.63%
Earnings per share change (TTM)
-58.54%
3-year revenue growth (CAGR)
5.20%
3-year earnings per share growth (CAGR)
-38.67%
What the Analysts think about Shattuck Labs
Analyst ratings (Buy, Hold, Sell) for Shattuck Labs stock.
Analyst projections of the future price of Shattuck Labs stock.
Bulls say / Bears say
SL-325’s Phase 1 trial in healthy volunteers showed no serious adverse events, a 3.7% anti-drug antibody rate and more than three months of complete TL1A-to-DR3 blockade at doses of 1 mg/kg or higher. That supports a potentially clean safety profile, low immunogenicity and quarterly dosing. (SEC, BioSpace)
The company is taking SL-325 into the decisive test: a randomised, placebo-controlled Phase 2b Crohn’s disease trial expected to start in the third quarter of 2026. Its induction and maintenance design, with endoscopic response assessed at Week 12, creates a clear clinical value catalyst. (Last10K, SEC)
SL-325 has so far shown target engagement and tolerability in healthy volunteers, not clinical benefit in Crohn’s disease. The upcoming Phase 2b study is therefore the first real test of whether the mechanism improves patients’ disease outcomes. (AllMind News, SEC)
The drug must prove a meaningful endoscopic and maintenance advantage against established IL-23 and anti-TNF therapies, as well as emerging TL1A competitors. Until patient data arrive, comparisons based on healthy-volunteer pharmacology and cross-trial immunogenicity remain uncertain. (AllMind News, Seeking Alpha)
Shattuck has no revenue and reported a $15.2 million second-quarter loss, while research spending is rising as it advances SL-325 and SL-846. Its stated cash runway into 2029 depends on current plans and excludes extra clinical costs, so delays or broader development could lead to further share dilution or funding needs. (StockTitan, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
Shattuck Labs Financial Performance
Revenues and expenses
Shattuck Labs Earnings Performance
Company profitability
Upcoming events
No upcoming events
Shattuck Labs News
AllArticlesVideos
Funds containing Shattuck Labs
AllEURGBP
Fund name | Fund size | $STTK weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.